HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trial

被引：0
|
作者：
Li, S. [1 ]
Lu, L. [1 ]
Wang, Q. [2 ]
Zhao, R. [3 ]
Mei, J. [1 ]
Li, J-B. [4 ]
Zheng, L. [5 ]
Wei, W. [3 ]
Guo, R. [3 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Liver Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Radiat Oncol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Liver Surg, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Clin Res, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ Canc Ctr, Dept Imaging, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
982P
引用
收藏
页码：S670 / S671
页数：2
相关论文
共 50 条
  • [31] A phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Furuse, J.
    Ikeda, M.
    Okusaka, T.
    Nakachi, K.
    Morizane, C.
    Ueno, H.
    Yamaura, H.
    Inaba, Y.
    Satake, M.
    Arai, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.
    Li, Shaohua
    Mei, Jie
    Cheng, Yuan
    Li, Qiang
    Wang, Qiaoxuan
    Fang, Chongkai
    Lei, Qiucheng
    Huang, Huakun
    Cao, Mingrong
    Luo, Rui
    Deng, Jingduo
    Jiang, Yuchuan
    Zhao, Rongce
    Lu, Lianghe
    Zou, Jingwen
    Zheng, Lie
    Wei, Wei
    Chen, Huanwei
    Zhong, Chong
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study
    Guo, Wenbo
    Gao, Jian
    Zhuang, Wenquan
    Wu, Zhiqiang
    Li, Bin
    Chen, Song
    JGH OPEN, 2020, 4 (03): : 477 - 483
  • [34] Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial
    Ren, Yupeng
    Li, Yuxuan
    Cao, Mingbo
    Tang, Yongchang
    Yuan, Feng
    Yang, Gaoyuan
    He, Zhiwei
    Shi, Zheng
    Su, Xiaorui
    Yao, Zhicheng
    Deng, Meihai
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (02)
  • [35] Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma:A single-center, prospective,single-arm clinical trial
    Yupeng Ren
    Yuxuan Li
    Mingbo Cao
    Yongchang Tang
    Feng Yuan
    Gaoyuan Yang
    Zhiwei He
    Zheng Shi
    Xiaorui Su
    Zhicheng Yao
    Meihai Deng
    ChineseJournalofCancerResearch, 2024, 36 (02) : 114 - 123
  • [36] Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study
    Chen, Ruiqing
    Li, Lingbing
    Li, Ye
    Song, Ke
    Shen, Chenyu
    Ma, Pengkai
    Wang, Zhijun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1367 - 1375
  • [37] Phase II trial of hepatic arterial infusion chemotherapy using cisplatin and 5-fluorouracil in patients with advanced hepatocellular carcinoma
    Tanaka, M
    Ando, E
    Yutani, S
    Fukumori, K
    Kuromatsu, R
    Shimauchi, Y
    Nagamatsu, H
    Matsugaki, S
    Itano, S
    Ono, N
    Sakisaka, S
    Sata, M
    PROGRESS IN HEPATOCELLULAR CARCINOMA TREATMENT, 2000, : 49 - 55
  • [38] Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
    Ikeda, M.
    Shimizu, S.
    Sato, T.
    Morimoto, M.
    Kojima, Y.
    Inaba, Y.
    Hagihara, A.
    Kudo, M.
    Nakamori, S.
    Kaneko, S.
    Sugimoto, R.
    Tahara, T.
    Ohmura, T.
    Yasui, K.
    Sato, K.
    Ishii, H.
    Furuse, J.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2090 - 2096
  • [39] Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial
    Nong, Xiang
    Zhang, Yu-Mei
    Liang, Jing-Chang
    Xie, Jin-Long
    Zhang, Zhi-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma: A meta-analysis and trial sequential analysis
    Yu, Jiahui
    Li, Yong
    Yu, Jinxin
    Yang, Yuting
    Chen, Yimiao
    Yi, Pengsheng
    EJSO, 2025, 51 (03):
12345